fbpx

BioTech

Predictmedix.png

PredictMedix: Value Meets Growth

Technology is different from every other sector by virtue of one important factor – it scales. Because technology is scaleable, firms penetrate international markets easily,

Read More »

I asked Twitter what tickers I should be writing about: Twitter had 35 ideas… here’s 6 of them

Ever get the feeling, looking at your watchlist, that you’re seeing the same thing over and over? That maybe there’s interesting stuff out there you just haven’t heard about yet? I put a simple question to Twitter today: “Give me a ticker symbol you think I should be writing about (limit one per person), three reasons you think it’s great, and one thing you’ll openly admit they need to do better.” I got 35. Gulp.

Read More »

Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news

Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.

Read More »

Did Aytu BioScience (AYTU.Q) just SpankChain the NASDAQ?

When a sector gets hot, small cap stocks can often get a bump by sidling up to the hot sector with a new product/idea/opportunity. When the dust clears, the intrinsic value of the new offering is typically deemed to be low. We saw it in 3D-printing, with Dung Beetle Treats. We saw it in weed with a $1 billion website that forgot to sell cannabis. We saw it in blockchain with a Cryptocoin for porno transactions.

Read More »

Equity Guru Podcasts